Mean changes in electrocardiographic parameters at the end of the double-blind treatment, safety population
| Group; mean ± SD | |||
|---|---|---|---|
| Parameter | Placebo, n = 176 | Levomilnacipran ER, 40 mg/day, n = 176 | Levomilnacipran ER, 80 mg/day, n = 180 |
| Heart rate, beats/min | |||
| Baseline | 65.3 ± 10.1 | 65.0 ± 10.0 | 63.0 ± 8.6 |
| Mean change | 1.1 ± 9.0 | 10.2 ± 11.4 | 12.7 ± 12.1 |
| QT interval, ms | |||
| Baseline | 398.5 ± 26.7 | 398.9 ± 27.2 | 404.8 ± 25.3 |
| Mean change | −4.6 ± 23.0 | −20.4 ± 24.4 | −26.7 ± 25.5 |
| QTcB interval, ms | |||
| Baseline | 412.8 ± 22.3 | 412.5 ± 22.5 | 413.2 ± 23.1 |
| Mean change | −1.6 ± 18.8 | 7.9 ± 21.5 | 8.5 ± 19.7 |
| QTcF interval, ms | |||
| Baseline | 407.7 ± 18.8 | 407.7 ± 19.2 | 410.2 ± 20.1 |
| Mean change | −2.6 ± 16.2 | −2.0 ± 16.4 | −3.9 ± 15.3 |
ER = extended-release; SD = standard deviation.